Drug Hunter
Drug Hunter
  • 29
  • 32 358
Coffee Chat: Unusual Motifs in Recent Clinical Candidates and Approved Drugs
As medicinal chemists, we're all curious about the structures of clinical candidates and drugs. In this Coffee Chat Dennis Hu, Lew Pennington, and Dennis Koester, highlight selected unusual motifs in clinical candidates and approved drugs using Drug Hunter’s new Structure Search tool, demonstrating how you can use the tool to generate ideas and pressure-test your designs before synthesis or extensive compound profiling.
During this session, the team discusses case studies leveraging unique motifs, such as azetidines, oxetanes, alkynes, and phosphorus- and boron-containing moieties, and how they impacted the discovery and properties of the molecules. The team fields live audience questions and topic suggestions. You'll gain transferable insights that you can apply to your own drug discovery programs.
Drug Hunter Speakers:
Dennis Hu Ph.D., CEO
Dennis Koester Ph. D., Director, Industry Research and Relations
Lew Pennington Ph.D., Scientific Director
00:00 Introduction
00:30 Dennis Hu Ph.D., CEO
12:41 Lew Pennington Ph.D., Scientific Director
22:57 Dennis Koester Ph.D., Director of Industry Research and Relations
32:36 Q&A
Don't miss out on future sessions of this new interactive series!
Register here: drughunter.com/coffee-chat-registration
Presented as part of the Drug Hunter Coffee Chat series on July 26, 2024
Переглядів: 470

Відео

About Drug Hunter
Переглядів 9421 годину тому
Every day, companies disclose discovery strategies, tactics, challenges and solutions, but the knowledge is fragmented across journals, conferences, patents, databases, news and endless other sources, making it challenging to find and apply. Drug Hunter connects the dots, distilling industry lessons from thousands of sources into a one-of-a-kind searchable platform for drug discovery knowledge ...
Design Principles in the Beyond Rule of 5 Space
Переглядів 1 тис.14 днів тому
Modern drug discovery is now capable of targeting previously considered undruggable targets. The complexity of medicines is increasing, with many drug molecules and modalities violating at least one of Lipinski's Rule of 5 (Ro5) parameters. In the "beyond Rule of 5" (bRo5) space, unique design principles are essential. Optimizing permeability and lipophilicity is particularly challenging due to...
VC Biotech Investing and Company Creation 101
Переглядів 528Місяць тому
Enjoy our recent conversation with Florencia Segal where we discussed the state of the biotech market. Florencia shared biotech startup success factors and common pitfalls, and what a career in venture capital entails. As an Infectious Diseases Physician-Scientist and a drug development leader, Florencia brings a unique perspective to the realm of investing. She is currently a Partner at MPM Bi...
Target Spotlight WRN Helicase
Переглядів 1,1 тис.Місяць тому
In this coffee chat we discussed one of our team's favorite targets: WRN helicase. During this session, the team delves into why WRN helicase has captured the attention of researchers and unpacked the intricacies of its mechanism of action. They also highlighted an intriguing approach to hit finding that has paved the way for the development of a WRN helicase inhibitor and evaluate compound dif...
Drug Hunter Case Study Overview
Переглядів 110Місяць тому
The traditional way we learn about the latest in drug discovery is a conference presentation or a journal club. You pick a colleague, ask them to spend two weeks researching a topic, and have the whole department sit in a room for an hour while your co-worker tells you what they learned. You’d be lucky to get through one topic a quarter - IF you can find co-workers that are willing to keep volu...
Minds & Molecules: Lessons from Alzheimer's Research
Переглядів 794Місяць тому
Despite limited success with amyloid-targeting biologics, Alzheimer's disease (AD) remains a neurodegenerative disorder in dire need of new directions and new thinking to augment ongoing approaches. Instead of seeking a single "magic bullet" for AD, a multifaceted approach is more likely to lead to success. Targets involved in neuroinflammation have emerged for the treatment of AD. 00:23 Introd...
Drug Induced Liver Injury - A Medicinal Chemist's Perspective
Переглядів 1,5 тис.Місяць тому
This talk provides a medicinal chemist's perspective on the current understanding of DILI mechanisms, highlight cutting-edge assay developments for a holistic assessment, and discuss strategies for predicting DILI risks. This session aims to equip medicinal chemists with working knowledge to manage DILI risks on their programs. 00:22 Introduction 02:04 Ice-breaker questions 08:27 Presentation 3...
A Guide to Generative AI for Medicinal Chemists, ​Presented by Ashwini Ghogare, Ph.D.
Переглядів 1,1 тис.2 місяці тому
Drug Hunter's Dennis Koester, Director of Industry Research and Relations, hosts a conversation with Ashwini Ghogare, Ph.D., the Head of AI & Automation in Drug Discovery at MilliporeSigma. ​This Flash Talk explores how generative AI can streamline drug discovery workflows for medicinal chemists, from hit identification to lead optimization. 00:00 - Welcome and Introduction 03:31- Introduction ...
Meet the Drug Hunter Team
Переглядів 2852 місяці тому
In case you missed our "Meet the Team" informal coffee chat, here's your chance to get to know the scientists behind Drug Hunter. Learn about their backgrounds, why they joined the team, their favorite molecule, and what they're most excited about in drug discovery. Don't miss out on future sessions of this new interactive series! Register here: drughunter.com/coffee-chat-registration Presenter...
Analysis of Successful Hit-to-Clinical Candidate Pairs
Переглядів 1,5 тис.3 місяці тому
Dean Brown, Ph.D. provides a compelling analysis of 156 clinical candidates published in the Journal of Medicinal Chemistry between 2018 and 2021. 00:00 - About Drug Hunter 04:04 - Introduction of Dr. Dean Brown 11:16 - Presentation commences 48:20 - Q&A Presented by Dean Brown, Ph.D. Jnana Therapeutics with Host Dennis Koester, Ph.D. Drug Hunter Access additional resources and browse previous ...
Relay PI3K Case Study Sneak Peek
Переглядів 5734 місяці тому
Host Dennis C. Koester, Ph.D. provides a walk-through of one of our popular case studies RLY-2608: An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models. Not at one of the 150 institutions with full Drug Hunter access? Learn how Drug Hunter helps you solve your greatest R&D challenges and request access here: drughunters.com/requestdemo
Drug Hunter Website Demo
Переглядів 3134 місяці тому
Host Dennis C. Koester Ph.D. takes viewers on a tour of Drug Hunter premium and the features of our website. Not at one of the 150 institutions with full Drug Hunter access? Learn how Drug Hunter helps you solve your greatest R&D challenges and request access here: drughunters.com/requestdemo
How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments
Переглядів 3,3 тис.4 місяці тому
Peptidic GLP-1R agonists have received significant media coverage over the past year for their astounding efficacy in several indications. Whilst most of the recent fanfare has been related to their role in weight loss, they have been a mainstay of the diabetes treatment landscape for the past two decades. In addition, GLP-1R agonists have recently shown efficacy in reducing heart disease risk ...
A Med Chemist's Guide to Formulation Options to Improve Oral Bioavailability
Переглядів 2,4 тис.7 місяців тому
This talk presents a high-level overview of formulation options for improving small molecule bioavailability, examples of how formulation can make a big impact to oral availability and drug dose, explain when and why they work, choosing a formulation based on molecule properties, and the pros and cons of increasingly adopted technologies like nanoparticle formulation for a small molecule drug d...
Recent Highlights in Covalent Drug Discovery
Переглядів 3,1 тис.10 місяців тому
Recent Highlights in Covalent Drug Discovery
Recent Highlights in Targeted Protein Degradation
Переглядів 3,2 тис.Рік тому
Recent Highlights in Targeted Protein Degradation
Not Your Grandparents' Drugs: How Drugs Changed Since the 70's..and What to Do About It
Переглядів 710Рік тому
Not Your Grandparents' Drugs: How Drugs Changed Since the 70's..and What to Do About It
Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
Переглядів 1,7 тис.Рік тому
Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
Visible Light Photoredox Chemistry at Commercial Scale by Kaid Harper
Переглядів 959Рік тому
Visible Light Photoredox Chemistry at Commercial Scale by Kaid Harper
From "Just Another Kinase" to a New Treatment for Myelofibrosis
Переглядів 960Рік тому
From "Just Another Kinase" to a New Treatment for Myelofibrosis
Drug Hunter Flash Talks | Strategies to Optimize Unbound Brain Concentrations with Dennis Koester
Переглядів 2,7 тис.Рік тому
Drug Hunter Flash Talks | Strategies to Optimize Unbound Brain Concentrations with Dennis Koester
Drug Hunter Flash Talks | Meet the Founder and CEO of a Billion-Dollar CDMO, Oliver Ju
Переглядів 311Рік тому
Drug Hunter Flash Talks | Meet the Founder and CEO of a Billion-Dollar CDMO, Oliver Ju
Recent Highlights in Drug Discovery: Q2/Q3 2022 Part 2
Переглядів 303Рік тому
Recent Highlights in Drug Discovery: Q2/Q3 2022 Part 2
Drug Hunter Flash Talk: Recent Highlights in Drug Discovery: Q2/3 '22 September 27th, 2022
Переглядів 412Рік тому
Drug Hunter Flash Talk: Recent Highlights in Drug Discovery: Q2/3 '22 September 27th, 2022
Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.
Переглядів 728Рік тому
Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.
Drug Hunter Flash Talk with Christian Gampe , Ph.D. August 17th, 12pm EST
Переглядів 626Рік тому
Drug Hunter Flash Talk with Christian Gampe , Ph.D. August 17th, 12pm EST
Part 2: Drug Hunter Flashtalks Highlights from 2022 Q1, May 12
Переглядів 3992 роки тому
Part 2: Drug Hunter Flashtalks Highlights from 2022 Q1, May 12
Drug Hunter Flashtalks Highlights from 2022 Q1, April 26
Переглядів 1,3 тис.2 роки тому
Drug Hunter Flashtalks Highlights from 2022 Q1, April 26

КОМЕНТАРІ

  • @user-mp4bc9qp2x
    @user-mp4bc9qp2x 29 днів тому

    great format. looking forward to more discussions

  • @lipingpettus6541
    @lipingpettus6541 Місяць тому

    What an amazing review! Thanks Anh.

  • @loveKG26
    @loveKG26 Місяць тому

    ua-cam.com/video/MqWwhggnbyw/v-deo.htmlsi=A_x1UhMXBwxuM6JB

  • @loveKG26
    @loveKG26 Місяць тому

    ua-cam.com/video/iwvvUabq2QI/v-deo.htmlsi=xV4LJpShk3o8_nBI

    • @loveKG26
      @loveKG26 Місяць тому

      ua-cam.com/video/VrNZ-yj5QYw/v-deo.htmlsi=K_eVuUv5OD_T8i3F

    • @loveKG26
      @loveKG26 Місяць тому

      ua-cam.com/video/1JDJoFAzHVI/v-deo.htmlsi=uh0al2YH3Qb86yiN

  • @loveKG26
    @loveKG26 Місяць тому

    Treat infections before the take over the human brain with damage and inflammation infection that’s toxic to any human neuron’s….. my neurologist wouldn’t so bye bye lost soul waste less useless service all to make a coin off anti epileptic drugs or many others lol thanks again for letting the issues cause me brain damage so I can have a life long chronic issue needing neurologist prescribed drugs. Nothing to say here about the non obstructive hydrocephalus deemed dementia a lot of the time LOL AGAIN WOW just ignore infection and physiology of the brain. Let it continue to have occurring damage inflammation neurodegenerative issues that could be attenuated but get ignored. Bye useless health services let me rot then. Been there done that seen neurologists up through the I iverstity network first 2014 then by 2020 my ventricles were so large I endured years of hydrocephalus I assume causing the epilepsy they said had no cause. lol again disappointing people look so highly to these places of fake therapy. I couldn’t get the autoimmune work up even though I told my neurologist steroids had me seizure free for almost 2 years again nothing their stupid anti epileptics could do….. Yes I see through them now after 4 neurologists of not ruling out my ear fullness been there for 14 years now same amount of years the seizures …. Chronic infections present with non acute signs and symptoms. I suppose lvl may have mastoiditis all ignored and not ruled out as causing me infection close or in my brain nor the autoimmune…. So just know they like to diagnose and adios quick to do such without proper work ups. No specialists would make sure I had no infection. The side my ears full hurts can’t sleep on it or it feels horrible the next day, hmmm!? Makes one like me think, RETHINK each thing I’m told. Wow even though an MRI SAID IT WAS INFECTION of MASTOID bilateral, 8 years after it became full one day only one ear. Told it’s not infection not an issue not a cause but it feels different the the other side it’s the side seizures are coming from and I see through all these types of people now after 14 years of studying them and their actions through my treatment and it’s only been a pill. Only thing required was to look for brain tumour in my MRI by them….. lol not safe. That’s not the only way physically a seizure can be produced in the human brain. Neurologists also disregard autoimmune issues and any physical issues like with the spine/nervous system…. Not safe for the patient.

  • @invictusfate7195
    @invictusfate7195 Місяць тому

    Thank you for the nice presentation. Does this mean that current ABeta targeting therapeutics such as donanemab could lead to increased infections in patients under treatment?

    • @loveKG26
      @loveKG26 Місяць тому

      Wow not good since infections and inflammation can cause amyloid….. leave the infection or inflammation not targeted and get a patient with memory and cognitive issues…. Time to play drug deals…..

  • @invictusfate7195
    @invictusfate7195 Місяць тому

    Informative presentation, thank you

  • @Mohakal777
    @Mohakal777 Місяць тому

    Thank you so much Dennis for bringing these great people to share their knowledge.

  • @gagankukreja2068
    @gagankukreja2068 Місяць тому

    Simply awesome.

  • @gagankukreja2068
    @gagankukreja2068 2 місяці тому

    How much AI assistance the team makes use of while writing these super exciting articles and how do you foresee AI contributing further in your journey. Thanks Gagan Kukreja

    • @drughunter
      @drughunter 2 місяці тому

      Hi Gagan, Thank you so much for this important question. We utilize ML and AI tools to helps us research and filter the vast amount of publications, patents and other sources produced every month. However, our validation and selection process is performed by experts in the field. All of our content is human-written and not generated by generative AI. Looking ahead, we envision further leveraging AI in research and in enhanced search, but it is hard to imaging AI displacing the level of scientific talent on the team!

  • @gagankukreja2068
    @gagankukreja2068 2 місяці тому

    Super inspiring. Besides compiling and sharing the literature, how important is for the Drug Hunter team to share their own independent insights, expert opinion/readout on the molecule being covered. Thanks Gagan Kukreja

    • @drughunter
      @drughunter 2 місяці тому

      Hi Gagan, Thanks for your kind words. At Drug Hunter, our mission is to share the knowledge and learnings acquired by drug discovery teams across the industry with scientists actively engaged in the drug discovery. We aim to facilitate easy access to the primary sources we use, enabling our readers to delve deeper into specific topics if the wish. In "Molecules of the Month" and "Patent Highlights" we follow a rigorous editorial selection process, as detailed by Dennis here: drughunter.com/blog/how-do-you-choose-the-molecules We believe that providing expert opinions is crucial, and we ensure our expressed opinions are well-grounded in facts and thorough analysis. Hope that helps.

  • @user-xs7nn5ip2p
    @user-xs7nn5ip2p 3 місяці тому

    could you list the reference for covalent binding to the backbone amine, it's really interesting! thank you!

  • @rez3vil
    @rez3vil 3 місяці тому

    This was very well summarized.

  • @mario97br
    @mario97br 4 місяці тому

    Good job nice

  • @petetroglodyte1860
    @petetroglodyte1860 4 місяці тому

    RLAY PI3K sucks

  • @Mohakal777
    @Mohakal777 7 місяців тому

    Thank you drug for sharing your talent of clear understanding in organized way.

  • @Finnnicus
    @Finnnicus 8 місяців тому

    I would love to see more presentations on process stories

  • @user-pe3nq2kz3v
    @user-pe3nq2kz3v 9 місяців тому

    Hi Dennis. I think there may be a misunderstanding. The EPSA means "exposed PSA" not experimental PSA. Please refer to the literature ACS Med. Chem. Lett. 2014, 5, 1167−1172; ACS Med. Chem. Lett. 2022, 13, 6, 964-971. As you mentioned, the intramolecular hydrogen bond of RMC-6291 may sheild the polarity of morpholine and amide, which results in a similar EPSA with compound 5

    • @drughunter
      @drughunter 9 місяців тому

      Thank you for your comment! In the original Pfizer paper(s), EPSA (an experimentally determined value from chromatography) was named EPSA in analogy to their previous experimental measure, ELogD (see AMCL 2014). While the "E" wasn't defined in the paper, many started to refer to this as experimental PSA and others exposed PSA, though people are all generally referring to this method.

  • @zefix3133
    @zefix3133 Рік тому

    You have to study chemistry for these kind of tasks or is it possible with pharmacy as well?

    • @johnsviewsonspewtube
      @johnsviewsonspewtube Рік тому

      A person with a strong background in Organic Synthesis will best succeed in the area of process chemistry. Significant training in a Ph.D program along with post-doctoral training focusing in total synthesis of complex natural products is a likely optimal route for one to pursue, however, that's not to say that a chemist with extensive training in organic methodologies development and applications to total synthesis of natural products could not success just as well. I came from a Medicinal Chemistry graduate program and we had many people with Pharmacy backgrounds who succeeded very well in synthetic chemistry careers. Overall, it's important to understand a breadth of organic reactions, mechanistic understanding and hands on applications from milligram to multi-gram scale. To transition to process, a deep understanding of physical organic chemistry becomes important since these considerations must be accounted for when working on kilogram scales. I worked in a pharma med chem lab for a decade and now in project management for the federal government, and hold process chemists in the highest respects for their elegance and optimization of initial synthetic routes. Good luck in you endeavors ~John

  • @noriegajoel599
    @noriegajoel599 Рік тому

    What would you have chosen, to live with herpes virus, CFS/ME (etc)forever or go for the herpes virus, CFS/ME proven medicine that has worked immensely in curing people from _Dr Madida_ /-/\-\